MICHELLE ALLEN: Open Payments
NPI 1922540822 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$819 in 28 payments from 13 companies in 2025. Trend: 2023 $80 · 2024 $0 · 2025 $819
Food & beverage: $819
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $282 |
| GENZYME CORPORATION | 4 | $92 |
| Novartis Pharmaceuticals Corporation | 3 | $86 |
| CSL Behring | 2 | $61 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $58 |
| Galderma Laboratories, L.P. | 2 | $50 |
| ABBVIE INC. | 2 | $34 |
| Organon LLC | 1 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $26 |
Products named: TEZSPIRE, Rhapsido, AIRSUPRA, DUPIXENT, Hizentra, NEFFY, NEMLUVIO, FASENRA.
Industry payments across TX — which companies pay providers there.
